Literature DB >> 3345870

Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis.

C H Hobson1, T J Butt, D M Ferry, J Hunter, V S Chadwick, M F Broom.   

Abstract

The association of hepatobiliary disorders with colonic inflammation is well recognized. Although the pathophysiology is obscure, increased permeation of toxic bacterial products across the inflamed gut to the portal circulation might be one mechanism. Potentially toxic metabolites include N-formylated chemotactic peptides that are produced by several species of intestinal bacteria and can be detected in colonic fluid in vivo. To investigate the metabolic fate of one of these low molecular weight proinflammatory peptides, N-formyl L-methionine L-leucine 125I-L-tyrosine was introduced into colon loops of healthy rats (n = 10) and rats with experimental colitis (n = 15) induced by rectal instillation of 15% (vol/vol) acetic acid. Gut, liver, and blood radioactivity were monitored by external gamma-counting and radioactivity in bile was measured by biliary catheter drainage into a well counter. Bile was processed by high-performance liquid chromatography to determine the amount of intact, bioactive peptide excreted over 3 h. After colonic instillation of 1 nmol of peptide, the mean (+/- SEM) biliary excretion of intact peptide was 6.4 +/- 2.0 pmol in normal rats and 49.0 +/- 20 pmol in rats with colitis (p less than 0.01). An enterohepatic circulation of synthetic N-formyl L-methionine L-leucine L-tyrosine has been demonstrated in the rat. Experimental colitis was associated with an eightfold increase in biliary excretion of this proinflammatory bacterial peptide. Proinflammatory bacterial peptides synthesized by colonic bacteria could be important in the pathophysiology of colon inflammation and its frequently associated hepatobiliary complications.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345870     DOI: 10.1016/0016-5085(88)90560-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Extraintestinal manifestations of granulomatous enterocolitis induced in rabbits by long-term submucosal administration of muramyl dipeptide emulsified with Freund's incomplete adjuvant.

Authors:  K Kuroe; Y Haga; O Funakoshi; I Mizuki; K Kanazawa; Y Yoshida
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

3.  Effects of inhalation of N-formyl-methionyl-leucyl-phenylalanine in the well elderly and in patients with chronic bronchitis.

Authors:  M J Peters; A B Breslin; N Berend
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

Review 4.  Animal models of inflammatory bowel disease.

Authors:  M A Bhatti; H J Hodgson
Journal:  Int J Exp Pathol       Date:  1995-10       Impact factor: 1.925

5.  Cutting edge issues in primary sclerosing cholangitis.

Authors:  Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

6.  Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.

Authors:  Y R Mahida; K C Wu; D P Jewell
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

Review 7.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

8.  Acetic acid-induced colitis results in bystander ileal injury.

Authors:  L R Empey; N Cui; R N Fedorak
Journal:  Agents Actions       Date:  1993-01

9.  Hepatobiliary excretion of bacterial formyl-methionyl peptides in rat. Structure activity studies.

Authors:  R P Anderson; T J Butt; V S Chadwick
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.